Angelo Antonini

Summary

Publications

  1. ncbi New strategies in motor parkinsonism
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento Milano, Italy
    Parkinsonism Relat Disord 13:S446-9. 2007
  2. ncbi Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report
    Mattia Gambarin
    Dipartimento di Scienze Neurologiche e della Visione, Sezione di Neurologia Riabilitativa, , Verona, Italy
    Mov Disord 21:270-3. 2006
  3. ncbi Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Lancet Neurol 6:826-9. 2007
  4. ncbi Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease
    A Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italia
    Neurodegener Dis 5:244-6. 2008
  5. ncbi Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
    Angelo Antonini
    Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
    Neurol Sci 34:683-7. 2013
  6. ncbi The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life
    Angelo Antonini
    Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
    J Neurol 259:2621-31. 2012
  7. ncbi Role of pramipexole in the management of Parkinson's disease
    Angelo Antonini
    Department for Parkinson Disease, IRCCS San Camillo, Venice, Italy
    CNS Drugs 24:829-41. 2010
  8. ncbi Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders
    Angelo Antonini
    Department for Parkinson s Disease, IRCCS San Camillo, Venice, Italy
    Funct Neurol 25:21-5. 2010
  9. ncbi Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Parkinsonism Relat Disord 15:S97-100. 2009
  10. ncbi Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease
    Angelo Antonini
    IRRCS, San Camillo, Viale Alberoni 70, Venice, Italy
    CNS Drugs 24:119-29. 2010

Detail Information

Publications77

  1. ncbi New strategies in motor parkinsonism
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento Milano, Italy
    Parkinsonism Relat Disord 13:S446-9. 2007
    ..Interestingly, this procedure produces a satisfactory therapeutic response that is paralleled by a reduction in dyskinesia severity...
  2. ncbi Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report
    Mattia Gambarin
    Dipartimento di Scienze Neurologiche e della Visione, Sezione di Neurologia Riabilitativa, , Verona, Italy
    Mov Disord 21:270-3. 2006
    ..Because dopamine transporter imaging revealed bilateral and symmetrical reduction of striatal uptake, we suggest that PS is not primarily related to side differences in dopaminergic denervation or drug exposure...
  3. ncbi Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Lancet Neurol 6:826-9. 2007
    ..Because of the clinical consequences of the adverse reactions, we suggest that affinity for 5-HT(2B) receptors is routinely tested in future drugs, in the laboratory or in animals, before they are given to patients...
  4. ncbi Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease
    A Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italia
    Neurodegener Dis 5:244-6. 2008
    ..The use of apomorphine infusion is limited by compliance while deep brain stimulation is feasible only for a small number of patients mostly because of age constraints...
  5. ncbi Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
    Angelo Antonini
    Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
    Neurol Sci 34:683-7. 2013
    ..The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now available for use. This protocol will serve as outline for further validation of this in multiple languages...
  6. ncbi The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life
    Angelo Antonini
    Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
    J Neurol 259:2621-31. 2012
    ..These results have consequences for drug studies targeting non-motor features...
  7. ncbi Role of pramipexole in the management of Parkinson's disease
    Angelo Antonini
    Department for Parkinson Disease, IRCCS San Camillo, Venice, Italy
    CNS Drugs 24:829-41. 2010
    ..Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects...
  8. ncbi Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders
    Angelo Antonini
    Department for Parkinson s Disease, IRCCS San Camillo, Venice, Italy
    Funct Neurol 25:21-5. 2010
    ..Furthermore, the rationale for the treatment of PD with the rotigotine transdermal patch is discussed, focusing in particular on the related sleep disorders...
  9. ncbi Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Parkinsonism Relat Disord 15:S97-100. 2009
    ..This has consequences in resource allocation and in estimating cost-benefit ratios for these complex therapies in advanced PD...
  10. ncbi Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease
    Angelo Antonini
    IRRCS, San Camillo, Viale Alberoni 70, Venice, Italy
    CNS Drugs 24:119-29. 2010
    ..We propose a treatment algorithm that takes into account all currently available levodopa-based treatment strategies for motor complications in patients with PD...
  11. ncbi Continuous dopaminergic stimulation--from theory to clinical practice
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Parkinsonism Relat Disord 13:S24-8. 2007
    ..Duodenal levodopa produced significant clinical benefit without behavioural changes and allowed patients to discontinue all other PD medications. Duodenal levodopa should be considered in PD patients with advanced disease...
  12. ncbi Wearing-off scales in Parkinson's disease: critique and recommendations
    Angelo Antonini
    Department for Parkinson s Disease and Movement Disorders, IRCCS San Camillo, Venice, Italy
    Mov Disord 26:2169-75. 2011
    ..Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed...
  13. ncbi Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management
    Angelo Antonini
    Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Via Bignami 1, Milan, Italy
    Expert Rev Neurother 9:859-67. 2009
    ..We also address the issue of selection criteria and propose clinical characteristics of candidates to help the clinician choose the most suitable option for their patients...
  14. ncbi Single photon-emission computed tomography imaging in early Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, 20126 Milan, Italy
    Expert Rev Neurother 8:1853-64. 2008
    ..We will also discuss the role of imaging of monoaminergic nondopamine systems to assess nonmotor features...
  15. ncbi Pharmacokinetic evaluation of pramipexole
    Angelo Antonini
    Department for Parkinson Disease, IRCCS San Camillo, Venice, Italy
    Expert Opin Drug Metab Toxicol 7:1307-14. 2011
    ..Additional advantages could include the opportunity to provide more continuous drug delivery in a fashion that could help minimize dyskinesia risk, if the drug is used early in the disease course...
  16. ncbi Dopamine agonist-based strategies in the treatment of Parkinson's disease
    Angelo Antonini
    Istituti Clinici di Perfezionamento, Parkinson Institute, Via Bignami 1, Milan, Italy
    Neurol Sci 29:S371-4. 2008
    ..In this review we will examine factors contributing to treatment decision-making and discuss how a proper balance between motor and non-motor features should be aimed for in approaching PD therapy...
  17. ncbi Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Drug Saf 32:475-88. 2009
    ..Given the social and potentially medical-legal consequences of these behaviours, we encourage treating physicians to discuss risks with patients before treatment is initiated...
  18. ncbi Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 22:1145-9. 2007
    ..05). Two patients withdrew for adverse events. Our results demonstrate that a satisfactory therapeutic window can be achieved and maintained for several months in advanced PD patients...
  19. ncbi Continuous dopaminergic delivery in Parkinson's disease
    Angelo Antonini
    Department for Parkinson s Disease, IRCCS San Camillo and University of Padova, Venice, Italy
    J Neurol 257:S305-8. 2010
    ..Conversely, replacing whole oral therapy with levodopa infusion bypasses gastric emptying and avoids peaks and troughs in plasma by releasing levodopa in the duodenum/jejunum...
  20. ncbi Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy
    Angelo Antonini
    Parkinson Institute, Milan, Italy
    Mov Disord 23:2202-9. 2008
    ..123)I-FP-CIT SPECT is likely to be regarded as economically advantageous to differentiate ET from PD, increasing time on potentially beneficial therapy at a lower overall cost to the healthcare system...
  21. ncbi Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration
    Angelo Antonini
    Parkinson Institute and Neuroradiology, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 21:417-8. 2006
    ..These findings expand the genetic and imaging spectrum of this rare disorder...
  22. ncbi The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's disease
    Angelo Antonini
    Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Via Bignami 1, Milan, Italy
    Neurol Sci 29:S392-6. 2008
    ..This would reduce unnecessary internal medicine hospitalisations and further highlight the role of neurologists as a key health care figure...
  23. ncbi Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control study
    Roberto Cilia
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Clin Neurol Neurosurg 111:140-6. 2009
    ..Functional imaging evidenced pathological overactivity in motor cortical areas in advanced PD that can be normalized by effective therapies...
  24. ncbi Regression of cardiac valvulopathy related to ergot-derived dopamine agonists
    Renzo Zanettini
    Cardiac Rehabilitation Unit, Istituti Clinici diPerfezionamento, Via Bignami 1, Milan, Italy
    Cardiovasc Ther 29:404-10. 2011
    ..We followed-up our original cohort of patients to ascertain whether valvulopathy regressed after discontinuation of treatment and/or its incidence increased over time...
  25. ncbi Cognitive status of patients with Parkinson's disease and pathological gambling
    Chiara Siri
    Parkinson Institute, Istituti Clinici di Perfezionamento, 20126, Milan, Italy
    J Neurol 257:247-52. 2010
    ..In conclusion the occurrence of PG in our cohort of patients with PD was associated with preserved executive functions...
  26. ncbi A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20126, Milan, Italy
    J Neurol 258:579-85. 2011
    ..Decrement of medications was greater with STN-DBS. There was a significant worsening of NPI after STN-DBS, primarily because four subjects developed apathy...
  27. ncbi Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders
    Annamaria Vallelunga
    Molecular Neurobiology Laboratory, IRCCS San Camillo, via Alberoni 70, 35126 Venice Lido, Italy
    Parkinsonism Relat Disord 18:397-9. 2012
    ..We assessed whether allelic variants of dopamine D2 receptors (DRD2), catechol-O-methyltransferase (COMT) and dopamine transporter (DAT) were associated with the development of ICDs in PD...
  28. ncbi Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease
    Angelo Antonini
    Department of Neurology, Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 26:464-8. 2011
    ..However, impulsivity and compulsive symptoms have never been explored in PD patients before initiation of DRT. We previously reported a 20% of impulse control disorders (ICD) in an Italian cohort...
  29. ncbi LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample
    Stefano Goldwurm
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Parkinsonism Relat Disord 12:410-9. 2006
    ..Clinical features in carriers were those of typical, idiopathic Parkinson's disease. However, behavioural abnormalities were frequent (87%), suggesting a more widespread limbic involvement in G2019S carriers...
  30. ncbi Striatal dopamine transporter abnormalities in patients with essential tremor
    Ioannis U Isaias
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Nucl Med Commun 29:349-53. 2008
    ..Discriminant analysis was used to categorize healthy subjects and patients with Parkinson's disease or essential tremor...
  31. ncbi [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset
    Ioannis U Isaias
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan 20126, Italy
    Neuroreport 18:1499-502. 2007
    ..We conclude that widespread degeneration of the nigrostriatal dopaminergic pathway might be necessary for the development of parkinsonian tremor-at-rest...
  32. ncbi The PRIAMO study: background, methods and recruitment
    Angelo Antonini
    Parkinson Institute, Milan, Italy
    Neurol Sci 29:61-5. 2008
    ..PRIAMO has analysed a total of 1307 patients (out of 1325 initially enrolled). We expect that PRIAMO will substantially help to quantify the burden of NMS in patients with parkinsonism...
  33. ncbi Functional abnormalities underlying pathological gambling in Parkinson disease
    Roberto Cilia
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milano, Italy
    Arch Neurol 65:1604-11. 2008
    ..Pathological gambling (PG) may develop in patients with Parkinson disease (PD) during dopamine replacement therapy, but the underlying neural correlates are still unclear...
  34. ncbi Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study
    Roberto Cilia
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126, Milan, Italy
    Parkinsonism Relat Disord 13:290-4. 2007
    ..Worsening fluency was associated with perfusion decrements in left dorsolateral prefrontal cortex, anterior cingulate cortex and ventral caudate nucleus (p<.001)...
  35. ncbi Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire
    Chiara Siri
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20123, Milan, Italy
    Neurol Sci 31:35-40. 2010
    ..Psychopathological features are frequent in PD and their occurrence is underlined by disease-related factors...
  36. ncbi Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the α-synuclein gene
    Angelo Antonini
    Parkinson Department, IRCCS San Camillo, Venice, Italy
    J Neurol 259:165-7. 2012
    ..STN-DBS is safe and effective in patients with SNCA duplication showing a clinical pattern similar to idiopathic PD. Our case suggests that clinical phenotype rather genotype is the main predictor for DBS outcome...
  37. ncbi alpha-Synuclein multiplication analysis in Italian familial Parkinson disease
    Francesca Sironi
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milan, Italy
    Parkinsonism Relat Disord 16:228-31. 2010
    ..Although SNCA duplication is an unusual cause of familial PD testing for it is worthwhile. The clinical presentation of duplicated cases may be more aggressive than usual...
  38. ncbi Parkin analysis in early onset Parkinson's disease
    Francesca Sironi
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Parkinsonism Relat Disord 14:326-33. 2008
    ..735delT (p.C212/X224) and c.815C>G (p.C238W). Genotype-phenotype correlation revealed that parkin carriers had features similar to those of non-carrier early onset Parkinson disease patients...
  39. ncbi A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset
    Andrea Panzacchi
    Department of Nuclear Medicine, Scientific Institute San Raffaele, Milan, Italy
    Neurobiol Dis 31:102-9. 2008
    ..This work demonstrates that severity of nigrostriatal damage in early disease phase of sporadic PD is not dependent on age at onset. Genetically determined PD is associated with more severe and widespread dopaminergic impairment...
  40. ncbi Imaging essential tremor
    Ioannis U Isaias
    Department of Human Physiology, University of Milano, Milano, Italy
    Mov Disord 25:679-86. 2010
    ..In conclusion, PD and ET do not share a common pattern of dopaminergic loss over time. However, mild impairment of dopamine transporter in the caudate nucleus may contribute to tremor onset in ET...
  41. ncbi Cognitive bizarreness in the dream and waking mentation of nonpsychotic patients with Parkinson's disease
    Armando D'Agostino
    Department of Medicine, Surgery and Dentistry, Universita degli Studi di Milano, Milan, Italy
    J Neuropsychiatry Clin Neurosci 22:395-400. 2010
    ....
  42. ncbi The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy
    Gianni Pezzoli
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milan, Italy
    Clin Neurol Neurosurg 112:65-7. 2010
    ..GCSF can be safely administered to patients with atypical parkinsonism and potentially meaningful clinical changes may be observed in some patients. These results are encouraging and warrant further studies...
  43. ncbi Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease
    Francesco Vergani
    Neurosurgery Department, University of Milano Bicocca, Milan, Italy
    World Neurosurg 73:338-44. 2010
    ..Adverse events, due to surgical and hardware-related complications, must be clearly addressed to properly balance the cost-effectiveness of the therapy. In addition, limited data exists about medical adverse events after surgery...
  44. ncbi MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease
    Andrea Righini
    Department of Neuroradiology Istituti Clinici di Perfezionamento, Milan, Italy
    AJNR Am J Neuroradiol 25:927-32. 2004
    ..CONCLUSION: An abnormal superior profile of the midbrain facilitates the distinction of PSP from PD and may support the clinical differential diagnosis of parkinsonism...
  45. ncbi Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 21:1119-22. 2006
    ..However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment...
  46. ncbi Valvular heart disease and the use of dopamine agonists for Parkinson's disease
    Renzo Zanettini
    Cardiac Rehabilitation Unit, Istituti Clinici di Perfezionamento, Milan, Italy
    N Engl J Med 356:39-46. 2007
    ..Ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson's disease, have been associated with an increased risk of valvular heart disease...
  47. ncbi Dopamine Transporter SPECT Imaging in Corticobasal Syndrome
    Roberto Cilia
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    PLoS ONE 6:e18301. 2011
    ..In addition, we assessed prevalence and features of individuals with CBS and in vivo evidence of preserved nigral neuronal density...
  48. ncbi Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation
    Ioannis U Isaias
    Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 21:1144-7. 2006
    ..We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD...
  49. ncbi The relationship between impulsivity and impulse control disorders in Parkinson's disease
    Ioannis U Isaias
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 23:411-5. 2008
    ..Impulse control disorders are also common in the control population. Individual susceptibility factors, such as high impulsivity and depression, underline abnormal behaviors in PD patients treated with stable dopaminergic therapy...
  50. ncbi Extradural motor cortex stimulation in Parkinson's disease
    Roberto Cilia
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 22:111-4. 2007
    ..In our PD cohort, EMCS induced no objective benefit, although some subjective improvement was reported mostly on axial symptoms...
  51. ncbi Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease
    Roberta Biundo
    Department for Parkinson s Disease, Fondazione Ospedale San Camillo I R C C S, via Alberoni 70, Venice, Italy
    J Neural Transm 120:627-33. 2013
    ..These results have consequences for cognitive diagnosis and potentially in establishing the rate of PD cognitive decline...
  52. ncbi Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease
    Daniela Calandrella
    Department for Parkinson s Disease, Clinic San Pio X, Milan, Italy
    Parkinsonism Relat Disord 18:S120-2. 2012
    ..Infusion therapies may reverse motor complications in complicated patients with significant benefit on quality of life...
  53. ncbi Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities
    Roberta Biundo
    Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, 35126 Venice Lido, Italy
    J Neurol Sci 310:64-9. 2011
    ..Our results suggest that PD is characterized by an overall loss of gray matter in pre-frontal regions. However, the contribution of these changes to the development of ICDs is marginal...
  54. ncbi Clinical experience of tolcapone in advanced Parkinson's disease
    Margherita Canesi
    Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126, Milan, Italy
    Neurol Sci 29:S380-2. 2008
    ..Our findings indicate that tolcapone widens the levodopa therapeutic window, even in patients who have not benefited from entacapone. We suggest that tolcapone is indicated before patients are referred for more invasive procedures...
  55. ncbi Single-photon emission computed tomography in diagnosis and differential diagnosis of Parkinson's disease
    Ioannis U Isaias
    Department of Physiology, University of Milan, Milan, Italy
    Neurodegener Dis 7:319-29. 2010
    ....
  56. ncbi Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease
    Manuela Pilleri
    Department of Parkinson Disease and Movement Disorders, IRCCS San Camillo, Lido di Venezia, Venice, Italy
    J Neurol 260:253-9. 2013
    ..Our study confirms that there is an association between OH and selective cognitive deficits in PD, but rebuts the hypothesis that this is underlined by the development of cerebrovascular disease...
  57. ncbi Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease
    Andrea Righini
    Radiology and Neuroradiology Service, Hospital V Buzzi, Milan, Italy
    J Comput Assist Tomogr 26:266-71. 2002
    ..We evaluated the specificity and sensitivity of an acquisition protocol using thin section MRI to differentiate MSA-P from Parkinson disease (PD)...
  58. ncbi Pathological gambling in Parkinson's disease: disease related or drug related?
    Daniela Calandrella
    Parkinson s Disease Department, Clinic San Pio X, Milan, Italy
    Expert Rev Neurother 11:809-14. 2011
    ..This evidence is consistent with a significant contribution of disease-related factors...
  59. ncbi A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Lancet Neurol 8:929-37. 2009
    ..The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients...
  60. ncbi Bilateral subthalamic deep brain stimulation in a patient with Parkinson's disease who had previously undergone thalamotomy and autologous adrenal grafting in the caudate nucleus: case report
    Francesco Vergani
    Department of Neurosciences and Biomedical Technology, University of Milano-Bicocca, Milan, Italy
    Neurosurgery 59:E1140; discussion E1140. 2006
    ....
  61. ncbi COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento Milan, Italy
    Neuropsychiatr Dis Treat 4:1-9. 2008
    ..Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied...
  62. ncbi PET and SPECT functional imaging in Parkinson's disease
    Angelo Antonini
    Dipartimento di Neuroscienze, Centro per la malattia di Parkinson, Istituti Clinici di Perfezionamento, Via Bignami 1, 20125 Milan, Italy
    Sleep Med 5:201-6. 2004
    ..Conversely, the use of neuroimaging techniques can significantly shorten the diagnostic process and prove a useful means to the neurologist in those cases presenting with uncertain clinical diagnosis...
  63. ncbi Is there room for new non-dopaminergic treatments in Parkinson's disease?
    Manuela Pilleri
    Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
    J Neural Transm 120:349-52. 2013
    ....
  64. ncbi Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients
    Angelo Antonini
    Department for Parkinson s Disease, IRCSS San Camillo, Venice, Italy
    Neuropsychiatr Dis Treat 7:297-302. 2011
    ..Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course...
  65. ncbi [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase]
    Anna D'Ausilio
    Chiesi Farmaceutici, Parma
    Recenti Prog Med 94:484-93. 2003
    ....
  66. ncbi Pramipexole-treated Parkinson's disease during pregnancy
    Marco Mucchiut
    Clinica Neurologica, Policlinico Universitario, pzza Rodolone 2, 33013 Gemona del Friuli, Udine, Italy
    Mov Disord 19:1114-5. 2004
    ..The child, born by caesarean delivery, is healthy, whereas motor disability of the mother progressively increased to the point that levodopa therapy was necessary...
  67. ncbi Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism
    Andrew Feigin
    Center for Neuroscience, North Shore University Hospital, Manhasset, New York and New York University School of Medicine, New York, New York, USA
    Mov Disord 17:1265-70. 2002
    ..Because of significant individual subject overlap between groups, however, the clinical utility of this method in the differential diagnosis of Parkinsonism remains uncertain...
  68. ncbi Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study
    Giovanni Defazio
    Department of Neurology and Psychiatry, University of Bari, Piazza Giulio Cesare 11, I 70124 Bari, Italy
    Arch Neurol 65:1191-4. 2008
    ..To determine whether pain is more frequent among people with Parkinson disease (PD) than among age-matched controls...
  69. ncbi Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
    Alessio Di Fonzo
    Department of Clinical Genetics, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Eur J Hum Genet 14:322-31. 2006
    ..These data have implications both for understanding the molecular mechanisms of PD, and for directing the genetic screening in clinical practice...
  70. ncbi Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum
    Roberta Marongiu
    IRCCS CSS Mendel Institute, Rome, Italy
    Hum Mutat 28:98. 2007
    ..15445_15467del23) which produces several aberrant mRNAs. This report expands the genotypic spectrum of PINK1 mutations, with relevant implications for molecular analysis of this gene...
  71. ncbi Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation
    Maria Teresa Giordana
    Department of Neuroscience, University of Torino, Torino, Italy
    Mov Disord 22:275-8. 2007
    ..These findings support the concept that the neurodegeneration associated with LRRK2 mutations might be clinically and pathologically indistinguishable from typical PD...
  72. ncbi Anatomical identification of active contacts in subthalamic deep brain stimulation
    Francesco Vergani
    Department of Neurosciences and Medical Biotechnologies, University of Milano Bicocca, 20052 Monza, Italy
    Surg Neurol 67:140-6; discussion 146-7. 2007
    ..Identifying the location of active contacts for StnDBS can yield interesting insights on the mechanisms of action of DBS and the different role played by the anatomical structures of the subthalamic region...
  73. ncbi Role of DAT-SPECT in the diagnostic work up of parkinsonism
    Christoph Scherfler
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mov Disord 22:1229-38. 2007
    ..This review addresses the value of DAT-SPECT in early differential diagnosis, and its potential as a screening tool for subjects at risk of developing PD as well as issues around the assessment of disease progression...
  74. ncbi PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum
    Roberta Marongiu
    IRCCS CSS Mendel Institute, Rome, Italy
    Hum Mutat 29:565. 2008
    ..Hence, their significance should be kept distinct from that of homozygous/compound heterozygous mutations, that cause parkinsonism inherited in a mendelian fashion...
  75. ncbi Novel parkin mutations detected in patients with early-onset Parkinson's disease
    Aida M Bertoli-Avella
    Genetic Epidemiologic Unit, Department of Clinical Genetics and Department of Epidemiology and Biostatistics, Erasmus MC Rotterdam, The Netherlands
    Mov Disord 20:424-31. 2005
    ..This study confirms the frequent involvement of parkin and the importance of genetic testing in the diagnostic work-up of EOP...
  76. ncbi Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis
    Anne Grünewald
    Department of Neurology, University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Neurogenetics 8:103-9. 2007
    ..1366C>T mutation...
  77. ncbi Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study
    Paolo Barone
    Department of Neurological Sciences, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
    J Neurol 253:601-7. 2006
    ..We conclude that dopamine agonists may be an alternative to antidepressants in Parkinson's disease...